Tiny study probes diabetes Drug's Anti-Inflammatory power
NCT ID NCT06812429
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small study looked at how a class of diabetes drugs called SGLT2 inhibitors might reduce inflammation linked to heart and kidney disease. Six healthy adults took the medication for three days, and researchers measured changes in blood markers of inflammation. The goal was to understand the drug's effects, not to treat any condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a gentle yoga practice turn down the Body's pain and inflammation?
- Could a stress hormone be behind the hidden danger of low blood sugar?
- Grape powder may help aging immune systems — a trial puts it to the test
- A simple blood pressure cuff trick could shield the heart in kidney disease
- Can a sedative help rebuilt tissue survive after cancer surgery?
- Laser light may soothe brace pain without drugs